Effects of GCP on Prostate Cancer.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00269555|
Recruitment Status : Completed
First Posted : December 23, 2005
Last Update Posted : June 29, 2010
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Drug: Genistein Combined Polysaccharide (GCP)|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||62 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effects of a Genistein Combined Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.|
|Study Start Date :||May 2004|
|Primary Completion Date :||January 2006|
|Study Completion Date :||September 2006|
- Reduction in PSA serum levels.
- Stabilization of PSA serum levels.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00269555
|United States, California|
|University of California, Davis|
|Sacramento, California, United States, 95817|
|Principal Investigator:||Robert Hackman, PhD||University of California, Davis|
|Study Director:||Ralph W deVere White, MD||University of California, Davis|